Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples